Australasian Psychiatry
March 31, 2026
Shuichi Suetani, Faraz Honarparvar, Peter Muller et al.
Background Given that both attention-deficit hyperactivity disorder (ADHD) and cannabis use are known independent risk factors for psychosis, people with ADHD who consume cannabis may be especially vulnerable. The main objective of the current study was to explore the links between ADHD, cannabis use and psychosis outcomes. Methods A systematic review was conducted to examine the risk of...
Journal of psychopharmacology (Oxford, England)
November 19, 2025
Hillary Ung, Gemma Mckeon, Zorica Jokovic et al.
1 citation
Little is known about whether 3,4-methylenedioxy-N-methamphetamine (MDMA) neurocognitive side effects improve with sustained abstinence. This study aimed to systematically review and synthesise the existing literature on the long-term neurocognitive side effects of recreational MDMA use after a minimum of 6 months of abstinence. We searched relevant databases utilising terms related to (1) MDMA...
Journal of Affective Disorders
July 17, 2025
Alene Sze Jing Yong, Sue E Brennan, Suzie Bratuskins et al.
3 citations
Despite recent clinical and research interest, medical use of psychedelics has not been legalised in most jurisdictions. The Australian Therapeutic Goods Administration rescheduled methylenedioxymethamphetamine (MDMA) in July 2023 to permit authorised prescribing of MDMA for Post-traumatic Stress Disorder (PTSD) outside of the clinical trial setting. This manuscript describes the development of...
Australian & New Zealand Journal of Psychiatry
July 15, 2025
Zohaib Nadeem, Stephen Parker, Hugh McGovern et al.
7 citations
Background: Recent regulatory changes in Australia have approved 3,4-methylenedioxymethamphetamine for treating post-traumatic stress disorder and psilocybin for treatment-resistant depression. However, limited data exists on Australian mental healthcare providers’ attitudes, knowledge and readiness to implement with psychedelic-assisted psychotherapy. Methods: A cross-sectional survey was...
BMJ Open
April 1, 2025
Vanessa L. Beesley, Tom Kennedy, Fiona Maccallum et al.
2 citations
Introduction Prolonged grief disorder (PGD) represents a substantial public health issue, especially in oncology settings where it affects up to 30% of bereaved carers. Current best-practice treatments are lengthy, and up to 50% of participants have persistent PGD. Building on encouraging recent research with psychedelic-assisted therapies, the Psilocybin-Assisted suppoRtive psychoTherapy IN...
The Australian and New Zealand journal of psychiatry
October 1, 2024
Zohaib Nadeem, Stephen Parker, Hugh McGovern et al.
19 citations
Despite rapid advances in psychedelic sciences and the increasing number of countries legalizing psychedelics for the treatment of mental illnesses, the attitudes, knowledge and readiness of both mental health consumers and the general population remain largely unknown. A cross-sectional survey was conducted among Australians, targeting individuals with mental illness as potential mental health...
Progress in Brain Research
2019
Stephen Parker
15 citations
The study of consciousness within cognitive neuroscience has been dominated in recent years by investigations originating from collaborations between neuroscientific investigators and Buddhist meditation practitioners. The results have been remarkable, particularly when quantitative and qualitative research methods have been combined as they are in the neurophenomenological methodology...
Lena K. L. Oestreich, Hugh McGovern, Zohaib Nadeem et al.
preprint
Background: The therapeutic use of 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin has gained interest due to their potential efficacy in treating mental illness. We systematically reviewed the efficacy of MDMA and psilocybin in treating mental illness and explored the moderating effects of dosage, psychotherapeutic support, and concurrent antidepressant use. Methods: In this systematic...